JPRN-UMIN000003274
Completed
Phase 2
A phase II trial of gefitinib and concurrent radiation therapy for locally advanced non-small cell lung cancer patients harboring sensitive EGFR mutations. - A phase II trial of gefitinib and concurrent radiation therapy for locally advanced non-small cell lung cancer patients harboring sensitive EGFR mutations.
ational Hospital Organization0 sites15 target enrollmentMarch 1, 2010
Conditionson-small cell lung cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- on-small cell lung cancer
- Sponsor
- ational Hospital Organization
- Enrollment
- 15
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Patients with active severe infections 2\.Significant interstitial pneumonitis , pulmonary fibrosis on Chest CT 3\.Contralateral hilar lymph node metastasis 4\.Patietns with ileus 5\.Patients with uncontrollable diarrhea 6\.The presence of other concomitant cancers 7\.Serious allergy history 8\.Patients with total gastrectomy 9\.Heavy smoking habit: (the number of cigarettes smoked daily) x (smoking period)\> 400 10\.Tumor infiltrating great vessels clearly 11\.Patients harboring T790M mutation 12\.Inappropriate patients for this study judged by the physicians
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
Recruiting
Phase 1
A Phase I/II trial to evaluate gefitinib and concurrent postoperative chemoradiation in patients with advanced resectable head and neck cancerACTRN12605000510640peter maccallum Cancer Centre70
Completed
Phase 2
Randomized phase II study of continuous gefitinib plus chemotherapy versus alternation of gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive EGFR mutations (NEJ005/TCOG0902)on-small cell lung cancer with EGFR mutations (non-squamous histology)JPRN-UMIN000002789orth East Japan Study Group/The Tokyo Cooperative Oncology Group80
Completed
Not Applicable
A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutationslung adenocarcinomaJPRN-UMIN000002783agano lung cancer study meeting15
Recruiting
Phase 2
Randomised phase 2 trial of gefitinib plus bevacizumab vs gefitinib alone in patients with EGFR mutant non-squamous non small cell lung cancenon small cell lung cancerJPRN-UMIN000013586BAGEL study group90